| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2011.08.121 |
| P698 | PubMed publication ID | 21911022 |
| P50 | author | Juan M. Irache | Q43161954 |
| Carlos Gamazo | Q56995564 | ||
| P2093 | author name string | J de Souza | |
| A I Camacho | |||
| S Sánchez-Gómez | |||
| M Pardo-Ros | |||
| P2860 | cites work | Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine | Q21245322 |
| Biological functions and biogenesis of secreted bacterial outer membrane vesicles | Q24599020 | ||
| Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. | Q30368742 | ||
| Programming the magnitude and persistence of antibody responses with innate immunity | Q30400144 | ||
| Protective immunity of biodegradable nanoparticle-based vaccine against an experimental challenge with Salmonella Enteritidis in mice. | Q33282108 | ||
| The immunogenic SigA enterotoxin of Shigella flexneri 2a binds to HEp-2 cells and induces fodrin redistribution in intoxicated epithelial cells | Q33518453 | ||
| Rupture of the intestinal epithelial barrier and mucosal invasion by Shigella flexneri | Q33588750 | ||
| Virulence and immunomodulatory roles of bacterial outer membrane vesicles | Q33704480 | ||
| Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602 | Q33876803 | ||
| Vaccine adjuvants: current state and future trends | Q34358206 | ||
| Membrane vesicles shed by Legionella pneumophila inhibit fusion of phagosomes with lysosomes | Q34681272 | ||
| Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis | Q34983894 | ||
| Comparative analyses of proteins extracted by hot saline or released spontaneously into outer membrane blebs from field strains of Brucella ovis and Brucella melitensis | Q35095464 | ||
| Enterotoxigenic Escherichia coli secretes active heat-labile enterotoxin via outer membrane vesicles. | Q35141570 | ||
| Virulence factors are released from Pseudomonas aeruginosa in association with membrane vesicles during normal growth and exposure to gentamicin: a novel mechanism of enzyme secretion | Q35590092 | ||
| Shigella flexneri infection: pathogenesis and vaccine development. | Q35671854 | ||
| Aluminium compounds for use in vaccines | Q35915759 | ||
| Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. | Q36422508 | ||
| Lipopolysaccharide 3-deoxy-D-manno-octulosonic acid (Kdo) core determines bacterial association of secreted toxins | Q36475473 | ||
| Shigella's ways of manipulating the host intestinal innate and adaptive immune system: a tool box for survival? | Q36703588 | ||
| Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road | Q36844719 | ||
| Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides. | Q36966451 | ||
| Shigellosis: the current status of vaccine development | Q37151797 | ||
| Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children | Q37582928 | ||
| Inactivated and subunit vaccines to prevent shigellosis | Q37640115 | ||
| Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines | Q37857249 | ||
| Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine | Q37951381 | ||
| Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection | Q39822312 | ||
| Secretion of Ipa proteins by Shigella flexneri: inducer molecules and kinetics of activation. | Q39831093 | ||
| Enterotoxigenic Escherichia coli vesicles target toxin delivery into mammalian cells | Q40490533 | ||
| Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation | Q42117985 | ||
| Gantrez AN as a new polymer for the preparation of ligand-nanoparticle conjugates | Q44185143 | ||
| Th17 cells are the dominant T cell subtype primed by Shigella flexneri mediating protective immunity | Q44793040 | ||
| Salmonella-like bioadhesive nanoparticles | Q46560166 | ||
| Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity in vivo | Q50066630 | ||
| Vesicle-mediated export and assembly of pore-forming oligomers of the enterobacterial ClyA cytotoxin | Q50102555 | ||
| Development of a novel vaccine delivery system based on Gantrez nanoparticles. | Q51117082 | ||
| Role of Shigella flexneri 2a 34 kDa outer membrane protein in induction of protective immune response. | Q53618605 | ||
| Porin of Shigella dysenteriae activates mouse peritoneal macrophage through Toll-like receptors 2 and 6 to induce polarized type I response. | Q53619852 | ||
| Gantrez AN nanoparticles as an adjuvant for oral immunotherapy with allergens | Q57216501 | ||
| Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells | Q61276176 | ||
| Enhanced secretion through the Shigella flexneri Mxi-Spa translocon leads to assembly of extracellular proteins into macromolecular structures | Q64360979 | ||
| Serum antibody responses against shigella lipopolysaccharides and invasion plasmid-coded antigens in shigella infected Swedish patients | Q72715742 | ||
| Quantification of bacterial lipopolysaccharides by the purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation | Q77905496 | ||
| Stationary phase culture supernatant containing membrane vesicles induced immunity to rainbow trout Oncorhynchus mykiss fry syndrome | Q79343932 | ||
| T cells: TLRs deliver a direct hit to TH17 cells | Q84335259 | ||
| Sublingual vaccination with outer membrane protein of Porphyromonas gingivalis and Flt3 ligand elicits protective immunity in the oral cavity | Q84774619 | ||
| P433 | issue | 46 | |
| P921 | main subject | Shigella flexneri | Q1644417 |
| P304 | page(s) | 8222-8229 | |
| P577 | publication date | 2011-09-10 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice | |
| P478 | volume | 29 |
| Q28384520 | Advances in Integrative Nanomedicine for Improving Infectious Disease Treatment in Public Health |
| Q38284501 | An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children |
| Q24568229 | Bacterial outer membrane vesicles and vaccine applications |
| Q35611763 | Biological properties of extracellular vesicles and their physiological functions. |
| Q38114752 | Current methods for the isolation of extracellular vesicles. |
| Q28728768 | High yield production process for Shigella outer membrane particles |
| Q52365266 | IgG Responses to Porins and Lipopolysaccharide within an Outer Membrane-Based Vaccine against Nontyphoidal Salmonella Develop at Discordant Rates. |
| Q36927153 | Immunogenicity of mycobacterial vesicles in humans: identification of a new tuberculosis antibody biomarker |
| Q38199270 | Microbial biosynthesis of designer outer membrane vesicles. |
| Q63740213 | Mucosal vaccines and technology |
| Q39416800 | Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis |
| Q43623067 | Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice |
| Q36653379 | New technologies in developing recombinant attenuated Salmonella vaccine vectors |
| Q38947741 | Outer membrane vesicles in service as protein shuttles, biotic defenders, and immunological doppelgängers |
| Q27011190 | Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens |
| Q33416476 | Protection from hemolytic uremic syndrome by eyedrop vaccination with modified enterohemorrhagic E. coli outer membrane vesicles |
| Q36765670 | Quantitative proteomic analysis of Shigella flexneri and Shigella sonnei Generalized Modules for Membrane Antigens (GMMA) reveals highly pure preparations |
| Q40821392 | Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles |
| Q87419447 | Towards a non-living vaccine against Shigella flexneri: from the inactivation procedure to protection studies |
| Q93012662 | Towards a subunit vaccine from a Shigella flexneri ΔtolR mutant |
Search more.